

P Joseph Gibson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11648708/publications.pdf>

Version: 2024-02-01

11
papers

424
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

491
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Notifiable Disease Case Reporting Through Electronic Information Exchange—Facilitated Decision Support: A Controlled Before-and-After Trial. <i>Public Health Reports</i> , 2020, 135, 401-410.	2.5	6
2	Completeness and timeliness of notifiable disease reporting: a comparison of laboratory and provider reports submitted to a large county health department. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 87.	3.0	20
3	Characterizing Informatics Roles and Needs of Public Health Workers. <i>Journal of Public Health Management and Practice</i> , 2015, 21, S130-S140.	1.4	18
4	Estimating Increased Electronic Laboratory Reporting Volumes for Meaningful Use: Implications for the Public Health Workforce. <i>Online Journal of Public Health Informatics</i> , 2014, 5, 225.	0.7	17
5	Effectiveness and Cost of Risperidone and Olanzapine for Schizophrenia. <i>CNS Drugs</i> , 2005, 19, 393-410.	5.9	17
6	Response to Vocational Rehabilitation During Treatment With First- or Second-Generation Antipsychotics. <i>Psychiatric Services</i> , 2004, 55, 59-66.	2.0	23
7	The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population. <i>Value in Health</i> , 2004, 7, 22-35.	0.3	57
8	Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. <i>Schizophrenia Research</i> , 2004, 70, 331-342.	2.0	156
9	Open access to innovative drugs: treatment substitutions or treatment expansion?. <i>Health Care Financing Review</i> , 2004, 25, 35-53.	1.8	6
10	Role of Ethnicity in Predicting Antipsychotic Medication Adherence. <i>Annals of Pharmacotherapy</i> , 2003, 37, 625-630.	1.9	72
11	Atypical Antipsychotics in First Admission Schizophrenia: Medication Continuation and Outcomes. <i>Schizophrenia Bulletin</i> , 2003, 29, 519-530.	4.3	32